JP2025520232A5 - - Google Patents
Info
- Publication number
- JP2025520232A5 JP2025520232A5 JP2023547426A JP2023547426A JP2025520232A5 JP 2025520232 A5 JP2025520232 A5 JP 2025520232A5 JP 2023547426 A JP2023547426 A JP 2023547426A JP 2023547426 A JP2023547426 A JP 2023547426A JP 2025520232 A5 JP2025520232 A5 JP 2025520232A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- cancer
- acid sequence
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210712836.9 | 2022-06-22 | ||
| CN202210712836 | 2022-06-22 | ||
| PCT/CN2023/087998 WO2023246247A1 (zh) | 2022-06-22 | 2023-04-13 | 药物组合物及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025520232A JP2025520232A (ja) | 2025-07-03 |
| JP2025520232A5 true JP2025520232A5 (enExample) | 2026-04-15 |
Family
ID=89218472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023547426A Pending JP2025520232A (ja) | 2022-06-22 | 2023-04-13 | 医薬組成物及びその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250129163A1 (enExample) |
| EP (1) | EP4321537A4 (enExample) |
| JP (1) | JP2025520232A (enExample) |
| KR (1) | KR20250026284A (enExample) |
| CN (1) | CN117257934A (enExample) |
| AU (1) | AU2023287932A1 (enExample) |
| CA (1) | CA3208473A1 (enExample) |
| IL (1) | IL317556A (enExample) |
| MX (1) | MX2024015303A (enExample) |
| WO (1) | WO2023246247A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20250227A (es) | 2022-12-12 | 2025-06-30 | Lanova Medicines Ltd | Anticuerpos biespecíficos que se dirigen a pd1 y vegf |
| CN120714022A (zh) * | 2024-03-27 | 2025-09-30 | 康方汇科(上海)生物有限公司 | 药物组合及用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5747654A (en) | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
| EP4378957A3 (en) * | 2015-07-29 | 2024-08-07 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
| JP2021512624A (ja) * | 2018-02-11 | 2021-05-20 | ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッドＢｅｉｊｉｎｇ Ｈａｎｍｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． | 抗ｐｄ−１／抗ｖｅｇｆ天然抗体構造様ヘテロ二量体型二重特異性抗体及びその製造 |
| TWI823906B (zh) * | 2018-03-09 | 2023-12-01 | 美商艾吉納斯公司 | 抗-cd73 抗體及其使用方法 |
| CN110498857B (zh) * | 2019-08-09 | 2022-09-09 | 安徽瀚海博兴生物技术有限公司 | 一种抗vegf-抗pd1双特异性抗体 |
| BR112022010069A2 (pt) | 2019-11-25 | 2022-09-06 | Akeso Biopharma Inc | Anticorpo biespecífico, molécula de ácido nucleico isolada, vetor, célula hospedeira, conjugado, kit, uso do anticorpo biespecífico e composição farmacêutica |
| CN110960543A (zh) * | 2019-12-10 | 2020-04-07 | 安徽瀚海博兴生物技术有限公司 | 一种联合抗vegf-抗pd1双特异性抗体用于制备抗癌药物 |
| TWI813934B (zh) * | 2020-01-21 | 2023-09-01 | 大陸商甫康（上海）健康科技有限責任公司 | 一種雙特異性抗pd-l1/vegf抗體及其用途 |
| KR20230004726A (ko) * | 2020-04-22 | 2023-01-06 | 아케소 바이오파마, 인크. | 항-cd73/항-pd-1 이중특이항체 및 이의 용도 |
| KR20230004725A (ko) * | 2020-04-22 | 2023-01-06 | 아케소 바이오파마, 인크. | 항-cd73 항체 및 이의 용도 |
| CN114380915B (zh) * | 2020-10-19 | 2024-03-22 | 中山康方生物医药有限公司 | 抗cd73的抗体及其用途 |
-
2023
- 2023-04-13 US US18/264,242 patent/US20250129163A1/en active Pending
- 2023-04-13 CA CA3208473A patent/CA3208473A1/en active Pending
- 2023-04-13 IL IL317556A patent/IL317556A/en unknown
- 2023-04-13 EP EP23745372.5A patent/EP4321537A4/en active Pending
- 2023-04-13 AU AU2023287932A patent/AU2023287932A1/en active Pending
- 2023-04-13 KR KR1020257001892A patent/KR20250026284A/ko active Pending
- 2023-04-13 JP JP2023547426A patent/JP2025520232A/ja active Pending
- 2023-04-13 CN CN202310398592.6A patent/CN117257934A/zh active Pending
- 2023-04-13 WO PCT/CN2023/087998 patent/WO2023246247A1/zh not_active Ceased
-
2024
- 2024-12-10 MX MX2024015303A patent/MX2024015303A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025506318A5 (enExample) | ||
| JP2023504003A5 (enExample) | ||
| JP2020019787A5 (enExample) | ||
| IL302078A (en) | Anti-CCR8 monoclonal antibodies and their uses | |
| JP2021514664A5 (enExample) | ||
| JP2022515318A5 (enExample) | ||
| IL276830B1 (en) | Anti-claudin 18.2 antibodies and their uses | |
| IL293241A (en) | Bispecific antibody, anti-1-pd, anti-vegfa, pharmaceutical preparation containing it and its use | |
| JP2020522486A5 (enExample) | ||
| JP2020502271A5 (enExample) | ||
| JP2021515559A5 (enExample) | ||
| JP2024509018A5 (enExample) | ||
| RU2009115363A (ru) | Антагонисты рецепторов для лечения метастатического рака | |
| JP2020510653A5 (ja) | Ｃｅａを標的にする多重特異性結合タンパク質 | |
| JP2025507817A5 (enExample) | ||
| JP2010535713A5 (enExample) | ||
| JP2020522474A5 (enExample) | ||
| JP2024538669A5 (enExample) | ||
| JP2023546743A5 (enExample) | ||
| JP2024515618A5 (enExample) | ||
| JP2008508858A5 (enExample) | ||
| JP2024536881A5 (enExample) | ||
| JP2024542192A5 (enExample) | ||
| JP2024534468A5 (enExample) | ||
| JP2024504331A5 (enExample) |